Roche Plans At-Risk Launch Of Mircera, But Offers Amgen A 20% Royalty
Executive Summary
Roche plans to move forward with an at-risk launch of Mircera (epoetin beta) if it does not receive a judicial ruling on its proposal to sell the anti-anemia drug at a reduced cost and pay Amgen a 20 percent royalty on sales. The company wants a court decision by the end of February
You may also be interested in...
Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission
Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S
Amgen v. Roche: Mircera Battle Continues In Court And At Trade Commission
Roche has agreed to the conditions set by a federal judge for the launch of its anti-anemia drug Mircera (epoetin beta) in the U.S
Court May Ask Roche To Pay Amgen 22.5 Percent Royalty To Market Mircera
A district court judge issued a preliminary injunction blocking Roche's launch of Mircera (epoetin beta) in the United States and suggested the terms under which Roche might begin selling its anti-anemia drug